Park et al. (Blood, 2010) established that the interaction between the coinhibitory ligand B7-H1 (PD-L1) and CD80 (B7-1) is required for the induction and maintenance of peripheral T-cell tolerance in mice: a monoclonal antibody (43H12) that blocks B7-H1/CD80 while sparing B7-H1/PD-1 enhanced T-cell expansion, prevented anergy induction, restored responsiveness of previously anergized T cells, and abrogated oral tolerance, with CD80 on T cells implicated as the signaling receptor. The mechanistic basis of this tolerogenic axis remains incomplete. The open questions are: (1) whether B7-H1 engages additional, currently unknown inhibitory receptor(s) beyond PD-1 and CD80 in vivo whose interaction with B7-H1 is susceptible to blockade by 43H12, and if so their identity, cellular distribution, and signaling consequences; (2) the cellular sources of B7-H1 — T-cell-intrinsic versus APC, regulatory-cell, myeloid-derived suppressor-cell, or parenchymal — and whether non-T-cell B7-H1 acts through PD-1, CD80, or both receptors in the induction and maintenance of tolerance; (3) whether selective disruption of the B7-H1/CD80 axis can achieve immunostimulation while minimizing the risk of autoimmunity, relative to nonselective blockade of both B7-H1 pathways. Later literature (2018-2025) characterized the cis and trans binding modes of PD-L1:CD80 structurally and functionally, established PD-L1-intrinsic reverse signaling, and demonstrated selective preclinical manipulation of the axis, but which geometry predominates for the tolerogenic interaction in vivo remains contested and none of these mechanistic questions is resolved in the tolerance setting. The problem is open.

Background

The B7:CD28 family of cosignaling molecules controls the balance between T-cell activation and tolerance. Its founding members CD80 (also called B7-1) and CD86 (B7-2) are expressed on antigen-presenting cells (APCs) and engage the costimulatory receptor CD28 and the inhibitory receptor CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) on T cells. A second branch comprises the inhibitory receptor PD-1 (programmed cell death-1), induced on activated T cells, and its ligands PD-L1 (also called B7-H1) and PD-L2. PD-L1 is inducibly expressed on APCs, parenchymal cells, activated T cells, and tumor cells, and the PD-1/PD-L1 axis is a central mechanism of peripheral T-cell tolerance — the constellation of mechanisms (anergy, deletion, regulation) that prevents autoreactive T cells from attacking self antigens. Anergy denotes a state of functional unresponsiveness into which activated T cells can be driven; oral tolerance denotes systemic unresponsiveness to fed antigens, a classic in-vivo model of peripheral tolerance. Butte et al. (2007) first showed that PD-L1 also binds CD80, at an interface overlapping both the PD-1 and CTLA-4/CD28 binding sites, and that this interaction inhibits T-cell activation — implying crosstalk between the two branches. Park et al. (2010) then showed, using the blocking antibody 43H12 together with B7-H1-deficient and CD80-deficient mice, that B7-H1/CD80 interaction is required for induction and maintenance of peripheral T-cell tolerance: blocking it prevented anergy, broke established tolerance, and abrogated oral tolerance, with CD80 upregulated on anergic T cells acting as the inhibitory signaling receptor. Two interacting molecules can engage 'in trans' (on opposing cells, e.g., PD-L1 on an APC binding PD-1 on a T cell) or 'in cis' (both on the same cell membrane). Starting in 2018 this geometry became contested: Chaudhri et al. (2018) reported that PD-L1 binds B7-1 only in cis on the same cell surface; Sugiura et al. (2019) and Zhao et al. (2019) showed that cis PD-L1:CD80 heterodimers on APCs block PD-L1 from engaging PD-1 while simultaneously activating CD28; yet Zhang et al. (2023) demonstrated that trans PD-L1/CD80 interactions between tumor cells and T cells also occur in vivo and can be blocked to augment antitumor immunity. Whether the tolerogenic interaction Park dissected operates in cis or in trans in vivo is itself unresolved, which compounds the original mechanism problem rather than settling it.

Problem Statement

Complete the mechanistic account of the B7-H1 (PD-L1)/CD80 axis in peripheral T-cell tolerance established by Park et al. (Blood, 2010), by answering the questions that the source work explicitly left open: (1) Does B7-H1 engage additional inhibitory receptor(s) beyond PD-1 and CD80 in vivo during tolerance induction — currently unknown receptor(s) of which the interaction with B7-H1 is susceptible to blockade by 43H12, as suggested by the residual stimulatory effect of 43H12 observed with CD80-deficient donor T cells — and if so, what is their identity, cellular distribution, and signaling consequence? (2) What are the relative contributions of T-cell-intrinsic versus non-T-cell (APC, regulatory-cell, myeloid-derived suppressor-cell, or parenchymal) sources of B7-H1 to the induction and the maintenance phases of peripheral T-cell tolerance, and does non-T-cell B7-H1 act through PD-1, CD80, both, or an additional receptor of the kind raised in (1)? In the adoptive-transfer setting, this dissection is confounded by the high baseline expansion of OT-I T cells in B7-H1-deficient hosts. (3) To what extent can selective disruption of the B7-H1/CD80 axis achieve immunostimulation (e.g., antitumor or recall responses, or an adjuvant effect for oral vaccines) while minimizing the risk of autoimmune responses, compared with nonselective blockade of both B7-H1 pathways? These questions concern the single mechanistic axis established by the source work: a causal, cell-level, and molecule-level explanation of how the PD-L1/CD80 interaction enforces peripheral tolerance, together with its selective therapeutic exploitation.

References

  1. Park JJ, Omiya R, Matsumura Y, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood. 2010;116(8):1291-1298. doi:10.1182/blood-2010-01-265975. https://doi.org/10.1182/blood-2010-01-265975
  2. Butte MJ, Keir ME, Phamduy TB, et al. Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses. Immunity. 2007. doi:10.1016/j.immuni.2007.05.016. https://doi.org/10.1016/j.immuni.2007.05.016
  3. Chaudhri A, Xiao Y, Klee A, et al. PD-L1 Binds to B7-1 Only in Cis on the Same Cell Surface. Cancer Immunology Research. 2018. doi:10.1158/2326-6066.CIR-17-0316. https://doi.org/10.1158/2326-6066.CIR-17-0316
  4. Sugiura D, Maruhashi T, Okazaki I, et al. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science. 2019. doi:10.1126/science.aav7062. https://doi.org/10.1126/science.aav7062
  5. Zhao Y, Lee C, Lin C, et al. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity. 2019. doi:10.1016/j.immuni.2019.11.003. https://doi.org/10.1016/j.immuni.2019.11.003
  6. Garrett-Thomson SC, Massimi A, Fedorov E, et al. Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex. PLOS ONE. 2020. doi:10.1371/journal.pone.0233578. https://doi.org/10.1371/journal.pone.0233578
  7. Zhang Y, Song Q, Cassady K, et al. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2205085120. https://doi.org/10.1073/pnas.2205085120
  8. Robinson M, Kennedy A, Orozco C, et al. Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction. Cell Reports. 2024. doi:10.1016/j.celrep.2024.114768. https://doi.org/10.1016/j.celrep.2024.114768
  9. Herold M, Posevitz V, Chudyka D, et al. B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway. The Journal of Immunology. 2015. doi:10.4049/jimmunol.1402746. https://doi.org/10.4049/jimmunol.1402746
  10. Xu D, Fu H, Obar J, et al. A Potential New Pathway for PD-L1 Costimulation of the CD8-T Cell Response to Listeria monocytogenes Infection. PLoS ONE. 2013. doi:10.1371/journal.pone.0056539. https://doi.org/10.1371/journal.pone.0056539
  11. Burke K, Chaudhri A, Freeman G, et al. The B7:CD28 family and friends: Unraveling coinhibitory interactions. Immunity. 2024. doi:10.1016/j.immuni.2024.01.013. https://doi.org/10.1016/j.immuni.2024.01.013
  12. Fukaya T, Takagi H, Sato Y, et al. Crucial roles of B7-H1 and B7-DC expressed on mesenteric lymph node dendritic cells in the generation of antigen-specific CD4+Foxp3+ regulatory T cells in the establishment of oral tolerance. Blood. 2010. doi:10.1182/blood-2009-10-250472. https://doi.org/10.1182/blood-2009-10-250472
  13. Yi T, Li X, Yao S, et al. Host APCs Augment In Vivo Expansion of Donor Natural Regulatory T Cells via B7H1/B7.1 in Allogeneic Recipients. The Journal of Immunology. 2011. doi:10.4049/jimmunol.1002939. https://doi.org/10.4049/jimmunol.1002939
  14. Fanelli G, Romano M, Nova-Lamperti E, et al. PD-L1 signaling on human memory CD4+ T cells induces a regulatory phenotype. PLOS Biology. 2021. doi:10.1371/journal.pbio.3001199. https://doi.org/10.1371/journal.pbio.3001199
  15. Ding Y, Chen C, Ma S, et al. Intrinsic PD-L1 promotes antitumor activity of CD8+ cytotoxic T lymphocytes via in cis interaction with CD80. Cancer Communications. 2022. doi:10.1002/cac2.12337. https://doi.org/10.1002/cac2.12337
  16. Mazerolles F. New expression of PD-L1 on activated CD4+ T cells opens up new opportunities for cell interactions and signaling. Human Immunology. 2024. doi:10.1016/j.humimm.2024.110831. https://doi.org/10.1016/j.humimm.2024.110831
  17. Rollins M, Gibbons Johnson R. CD80 Expressed by CD8+ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8+ T Cells. Journal of Immunology Research. 2017. doi:10.1155/2017/7659462. https://doi.org/10.1155/2017/7659462
  18. Kantheti U, Forward T, Lucas E, et al. PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration. Science Advances. 2025. doi:10.1126/sciadv.adt3044. https://doi.org/10.1126/sciadv.adt3044
  19. Kantheti U, Shirley J, Fry L, et al. PD-L1 cell-intrinsic signals limit immune activation during cutaneous vaccinia virus infection. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkaf368. https://doi.org/10.1093/jimmun/vkaf368
  20. Haile S, Dalal S, Clements V, et al. Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1-Mediated Immune Suppression. The Journal of Immunology. 2013. doi:10.4049/jimmunol.1202777. https://doi.org/10.4049/jimmunol.1202777
  21. Deng R, Cassady K, Li X, et al. B7H1/CD80 Interaction Augments PD-1-Dependent T Cell Apoptosis and Ameliorates Graft-versus-Host Disease. The Journal of Immunology. 2015. doi:10.4049/jimmunol.1402157. https://doi.org/10.4049/jimmunol.1402157
  22. Ni X, Song Q, Cassady K, et al. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. Journal of Clinical Investigation. 2017. doi:10.1172/jci91138. https://doi.org/10.1172/jci91138
  23. Sugiura D, Okazaki I, Maeda T, et al. PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity. Nature Immunology. 2022. doi:10.1038/s41590-021-01125-7. https://doi.org/10.1038/s41590-021-01125-7
  24. Bracey N, Maltzman J. Separation anxiety: Splitting PD-L1 from CD80 suppresses autoimmunity. Science Immunology. 2022. doi:10.1126/sciimmunol.abq1728. https://doi.org/10.1126/sciimmunol.abq1728